FDA panel: No can do on Mevacor OTC

Chalk up a third strike against over-the-counter statins. Yesterday, an FDA advisory panel voted overwhelmingly against allowing Merck to sell Mevacor without a prescription.

Drug makers--including Merck--have been trying for seven years to convert statins to over-the-counter status. The FDA rejected Merck's bid for OTC Mevacor in 1999 and again in 2005; officials declined to say whether they plan to try a fourth time.

At issue was whether the average Joe or Jane can safely self-medicate with a statin. Yesterday, Merck presented a study showing that almost three-fourths of consumers could. But the one-fourth remaining included patients at risk of serious side effects. Of course the fat lady--er, the FDA itself--hasn't sung yet. But the agency usually does take its panelists' advice. A decision is expected in late January.

- see the statement from Merck
- read the report from the Chicago Tribune

ALSO: Merck's CEO defines the perfect biotech buyout. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.